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Abstract
Background: Individuals with severe mental illness, e.g. schizophrenia have up to a 20% shortened life expectancy
compared to the general population. Cardiovascular disease, due to cardiometabolic risk and metabolic syndrome,
accounts for most of this excess mortality. A scoping search revealed that there has not been a review of published
studies on the role of pharmacy in relation to cardiometabolic risk, metabolic syndrome and related diseases (e.g.
type 2 diabetes) in individuals with severe mental illness.
Methods: A mixed-methods systematic review was performed. Eleven databases were searched using a
comprehensive search strategy to identify English-language studies where pharmacy was involved in an
intervention for cardiometabolic risk, metabolic syndrome or related diseases in severe mental illness in any study
setting from any country of origin. First, a mapping review was conducted. Then, implementation strategies used to
implement the study intervention were classified using the Cochrane Effective Practice and Organisation of Care
Taxonomy. Impact of the study intervention on the process (e.g. rate of diagnosis of metabolic syndrome) and
clinical (e.g. diabetic control) outcomes were analysed where possible (statistical tests of significance obtained for
quantitative outcome parameters reported). Quality assessment was undertaken using a modified Mixed Methods
Appraisal Tool.
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Results: A total of 33 studies were identified. Studies were heterogeneous for all characteristics. A total of 20
studies reported quantitative outcome data that allowed for detailed analysis of the impact of the study
intervention. The relationship between the total number of implementation strategies used and impact on
outcomes measured is unclear. Inclusion of face-to-face interaction in implementation of interventions appears to
be important in having a statistically significantly positive impact on measured outcomes even when used on its
own. Few studies included pharmacy staff in community or general practitioner practices (n = 2), clinical outcomes,
follow up of individuals after implementation of interventions (n = 3). No studies included synthesis of qualitative
data.
Conclusions: Our findings indicate that implementation strategies involving face-to-face interaction of pharmacists
with other members of the multidisciplinary team can improve process outcomes when used as the sole strategy.
Further work is needed on clinical outcomes (e.g. cardiovascular risk reduction), role of community pharmacy and
qualitative studies.
Systematic review registration: PROSPERO CRD42018086411
Keywords: Cardiometabolic, Metabolic, Pharmacy, Pharmacist, Severe mental illness, Monitoring, Screening,
Implementation, Guidelines, Cardiovascular disease
Background
Individuals with severe mental illness (SMI) (defined
here as bipolar affective disorder, schizophrenia, schi-
zoaffective disorder and other non-organic psychotic dis-
orders) have up to a 20% shortened life expectancy
compared to the general population [1]. The majority of
deaths in individuals with SMI are due to preventable
physical diseases, in particular, cardiovascular disease
(CVD) [1], they have a 2-3 times higher risk of dying
from CVD when compared to the general population
[1]. Evidence suggests that up to 75% of individuals with
schizophrenia (versus 33% of the general population) die
of CVD [1]. The remainder of deaths is due to unnatural
causes, including suicide, homicide and accidents [1].
These data have been well documented in meta-analyses
and systematic reviews [2–7]. The mortality gap exists in
countries considered to have high standards of health-
care [8] and can in part be accounted for by a higher
relative risk (around one- to fivefold) [9] for modifiable
cardiometabolic risk (CMR) factors.
CMR is a broad term that describes risk of CVD and
diabetes and includes the following: smoking [10–14],
overweight/obesity [14, 15], hyperglycaemia [13, 15],
hypertension [13, 14, 16], dyslipidaemia [14, 16, 17], and
metabolic syndrome (MetS) [18–24]. Public health data
from the United Kingdom (UK) [25] and the United
States of America (USA) [26] suggest that around two-
thirds of individuals with severe mental illness are
current smokers, a figure which reflects approximately
double that of the general population [25, 26]. A recent
systematic review and meta-analysis of 58 studies re-
ported that diet may often be poor [27] in individuals
with SMI, literature reviews indicate that overweight and
obesity is two- to threefold higher than that in the gen-
eral population [28, 29].
MetS is a more specific term that describes the
concurrence of the most dangerous CVD risk factors
[30–33]. MetS is defined by the International Diabetes
Federation as central obesity plus any two of the follow-
ing four factors: raised triglycerides (or specific treat-
ment for this), reduced HDL cholesterol (or specific
treatment for this lipid abnormality), raised blood pres-
sure (or treatment of previously diagnosed hypertension)
or raised fasting plasma glucose [32]. MetS is one of the
most prevalent risk factors for developing CVD in those
with SMI [34, 35]. Thirty-seven percent of those with
chronic schizophrenia have MetS [18] compared with
24% in the general population [18].
Antipsychotics, used to control psychotic symptoms in
people with SMI, are associated with physical side effects
including, dyslipidaemia, impaired glucose tolerance and
weight gain (more common with newer antipsychotics)
[36, 37]; the greatest weight gain has been reported to
occur in the first few months of use [36, 38, 39]. Weight
gain has also been shown to occur with antidepressants
(used to treat negative symptoms in SMI), and mood
stabilisers, including valproate/valproic acid and lithium
salts [40].
The likelihood of CMR, MetS or related diseases (e.g.
type 2 diabetes) is lower in young, drug-naïve individuals
and higher in individuals who have severe enduring illness
treated with medication (mainly antipsychotics) on a long-
term basis. Studies indicate that the CVD associated with
MetS in SMI may, to a certain extent, determined by gen-
etic risk factors [41]. In addition to antipsychotic medica-
tion, other factors including poor diet, physical inactivity,
high rates of smoking, obesity, overweight [42] and in-
equity to access to and quality of care [43–45] have been
reported to contribute. What is not known is the relative
contribution of each of these factors.
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The availability of rigorous economic data on this sub-
ject is limited. In a recent retrospective database review
of 57,506 patients with schizophrenia and bipolar dis-
order in the UK, each incremental CMR factor was asso-
ciated with an 8.3% and 13.4% increase in total hospital
spend respectively [46]. An estimated cost saving of £81
million/year could be made from an investment of £83
million in the physical health of those with SMI in pri-
mary care within the UK [47]; this cost saving could rise
to £108 million with sustained investment [47].
As far back as 1995, incorporating care for physical
health into the care of those with SMI was included in
government policies in parts of Australia [48]. In the
UK, guidelines for schizophrenia published by the Na-
tional Institute for Clinical Excellence (NICE) in 2002
[49] outlined recommendations for regular physical
health screening. Then, in 2004, as a result of a United
States of America (USA) Food and Drug Administra-
tion (FDA) warning about the association of antipsy-
chotics and elevated risk of type 2 diabetes, the
American Diabetes Association and the American
Psychiatry Association published joint guidelines that
clearly outlined the need for routine screening for
people taking antipsychotics [50]. Within the UK over
the past 5 years, much attention has been paid to
achieving parity between physical and mental health
[51, 52]. The terms screening and monitoring are
used interchangably here.
Despite the convincing evidence for increased CMR,
MetS and related diseases in individuals with SMI taking
antipsychotic medication as well as explicit recommen-
dations provided by guidelines, screening is often
incomplete or inconsistent [53]. A recent review of 39
internationally published studies suggested that rates of
routine baseline screening were low (50% only for blood
pressure and 59.9% for triglycerides) but less than 50%
for cholesterol (41.5%), glucose (44.3%), weight (47.9%)
and glycosylated haemoglobin (HbA1c) (< 25%) [53].
Timely and sustained interventions (e.g. lifestyle
changes) have been shown to reduce the incidence of
CMR, MetS and related diseases and in turn reduce pre-
mature morbidity, mortality and disability. Opportunistic
and other forms of screening by healthcare professionals
are therefore a potentially [54] useful means of detecting
risk factors, such as raised blood pressure, abnormal
blood lipids and blood glucose.
Systematic reviews have shown that patient interven-
tions delivered by pharmacists, have yielded positive ef-
fects on therapeutic, safety and clinical outcomes across
different diseases including diabetes and dyslipidaemia
[55–58]. These interventions included signposting and
advice in relation to health promotion as well as specific
risk reduction activities (e.g. smoking cessation) [55–57,
59, 60]. Outcomes include significantly improved mental
well-being, reduced risk of disease and premature mor-
tality [55–57, 59, 60].
Literature reviews conducted for those with mental
health conditions have shown that pharmacists provide a
variety of services and play a significant role in inpatient
mental healthcare [61]. Another review including studies
from both inpatient and outpatient mental health
settings concluded that pharmacists can have a positive
impact on outcomes, prescribing practices, patient satis-
faction and resource use [62]. Both reviews included
those with any type of mental health condition but did
not specify a breakdown of specific diagnoses.
We are not aware of any systematic reviews which
have specifically explored the nature or impact of phar-
macy involvement in CMR, Mets and related diseases
(e.g. diabetes, dyslipidaemia) in those with SMI.
Pharmacy staff (e.g. pharmacists, pharmacy techni-
cians) provide services and work collaboratively with pa-
tients, informal carers and care professionals to optimise
management of illness and disease. This is achieved pre-
dominantly through the provision of public health ser-
vices, e.g. smoking cessation, medicines optimisation,
access to medicines such as dispensing and enhanced
roles such as independent prescribing [63]. There has
not yet been a review of published studies to explore the
role of pharmacy/pharmacy staff in managing CMR or
MetS and related diseases in SMI. There is a potential
for pharmacy to have an impact on morbidity and mor-
tality associated with CMR, MetS, and related diseases in
those with SMI.
In 2018, the Royal Pharmaceutical Society of Great
Britain published a UK policy document which recom-
mended that the expertise and clinical knowledge of
pharmacists must be fully utilised to support people liv-
ing with mental health problems to ensure they live lon-
ger and healthier lives and reduce the mortality gap [64].
This policy included specific reference to the role of
pharmacists and pharmacy in relation to CMR, MetS
and related diseases in those with SMI.
There is growing recognition that both qualitative and
quantitative evidence can be combined in a mixed-
method analysis and synthesis and this can help in un-
derstanding how complexity impacts on interventions in
specific contexts. In particular, how complex interven-
tions work and for whom, and how the complex health
systems into which they are implemented respond and
adapt [65].
Aims and objectives
The primary aim of this systematic literature review is to
undertake a detailed analysis and review of the published
studies that exist relating to the role of pharmacy or
pharmacy staff in CMR, MetS and related diseases in in-
dividuals with SMI. This review seeks to undertake an
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exploration of the range of roles for pharmacy or phar-
macy staff as part of interventions relating to CMR, Mets
and related diseases, for example, undertaking screening
or managing CMR factor or advising on medication that
alters CMR risk. This could include, for example, a new
or existing pharmacy service or part of an intentional re-
search study intervention (the phrase study intervention
will be used here when referring to any of these). Sec-
ondary aims are to (i) undertake a review of implemen-
tation strategies used in study interventions and their
effectiveness in order to inform practice (ii) identify evi-
dence gaps to provide a focus for future research
studies.
The objectives are as follows:
(1) Identify published quantitative, qualitative or mixed
methods studies relating to the role of pharmacy or
pharmacy staff in CMR, MetS or related diseases in
individuals with SMI
(2) Summarise the data and conclusions from those
studies
(3) Undertake a collective appraisal of that data which
will consist of a mapping review and a detailed
analysis and review of the implementation strategies
used in study interventions that involved pharmacy
or pharmacy staff in CMR, MetS and related
diseases in SMI
(4) Identify limitations and evidence gaps from the
studies identified and make recommendations for
areas that require further research
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [66] were used
to standardise the conduct and reporting of the research
and the protocol was registered on PROSPERO: CRD
CRD42018086411. The PRISMA checklist is attached as
Additional file 1.
Literature search procedure and databases searched
A systematic search was conducted for primary studies
in which the study intervention involved pharmacy or
pharmacy staff in CMR, MetS or related diseases in SMI.
We included any published literature which described
an intervention involving pharmacy or pharmacy staff in
CMR, MetS or related diseases; this could include, for
example, a new pharmacy service or an existing service
or part of an intentional research study intervention.
Elaborating on what we mean by the term “role”, this
could include, for example, pharmacists or pharmacy
staff, undertaking screening (e.g. weight checks), man-
aging CMR factor (e.g. providing support for smoking
cessation) or advising on medication (e.g. advising on
switching medication with lower risk profile for weight
gain) (please see Table 1 PICOS criteria for detailed in-
formation on these interventions and Additional file 2).
Database-specific search strategies were developed
with assistance from a medical librarian. Eleven elec-
tronic databases were searched from inception to
January 2018; Medline, EMBASE, PsycINFO, British
Nursing Index, AMED, Health Business Elite, Health
Management Information Consortium, The Cochrane
Library, Health Technology Assessments, Scopus and
Web of Science (Additional file 2 provides detailed in-
formation on search strategy including, hand and grey
literature searches, and Population, Intervention,
Comparison, Outcome (PICOS)).
Study selection process
The eligibility criteria for full-text review are sum-
marised in Table 1 (more detailed information about in-
clusion and exclusion criteria for studies can be found in
Additional file 2: section 1.1). Studies were included if
they met the following inclusion criteria: English-
language, primary study, published in full, utilising
qualitative, quantitative or mixed methods. Only aspects
of the studies involving pharmacy or pharmacy staff
were extracted for analysis.
First, one author (DS) conducted preliminary screen-
ing of titles to exclude any publications that were clearly
not relevant (e.g. preclinical studies). Second, three au-
thors (DS, EL, RM) independently screened article titles
and abstracts against inclusion criteria, to identify poten-
tially relevant studies. Third, three authors (DS, EL, RM)
independently reviewed full texts of studies. Consensus
on inclusion was reached by discussion between three
authors (DS, EL, RM) when necessary, with senior
authors (EB or IM) available for arbitration if required
(see Additional file 2 Table 1.2 Reasons for excluding
studies after full-text review). Please refer to Fig. 1: PRIS
MA flow diagram of search results for further details.
Quality assessment
A modified Mixed Methods Appraisal Tool (Additional
file 2: 1.3 Quality assessment) was used to assess the
quality of included studies [67] by two authors (DS and
EL) independently. Consensus on scoring was reached
by discussion between authors with senior authors (IM
and EB) available for arbitration if required but this was
not needed.
Studies were not excluded on the assessed level of
quality but the quality assessment process enhanced
study interrogation and informed interpretation of the
results. In addition one of the main aims of this review
was to obtain an overview of all the research conducted
in this area, the authors (DS, EL, RM) agreed that exclu-
sion of studies would have potentially resulted in loss of
important data.
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The quality assessment conducted addressed threats to
external validity (e.g. risk of selection bias such as the
use of convenience sampling, lack of randomisation, lack
of control groups), threats to internal validity (e.g. con-
tamination between the pre and post groups for quasi
studies). None of the included studies reported under-
taking power analysis calculations to determine the
minimum number of participants they required. Please
see Additional file 2 for further information.
Summary of data extraction (study characteristics
and results) and collective appraisal
This was carried out in the following steps: summary of
study characteristics and conclusions, mapping review
and then an analysis and review implementation strat-
egies used in the study intervention. The lead author
(DS) utilised a reading support tool (Capti®) to listen to
each of the chosen studies three times. Two other au-
thors (EL and RM) read and re-read the included
studies. All three authors (DS, EL, RM) independently
extracted data regarding information contained within
each included study. Discrepancies were resolved
through discussion between three authors (DS, EL, RM).
The dataset was heterogeneous for all characteristics
including participant characteristics such as definition of
SMI and age, study setting, outcomes measured and data
collected.
A mapping review [68] (qualitative, quantitative
and mixed methods studies) conducted to obtain an
overview of the landscape of this particular research
area. It also facilitated the identification of trends or
themes as well as identification of specific gaps prior
to the more detailed analysis and review of imple-
mentation strategies used in study interventions [68].
Thirty of the studies included a study intervention that
could be classified into one of three categories (i) screen-
ing for CMR, MetS or related diseases (ii) screening,
identification of risk and implementation of
Table 1 Participants Intervention Comparator Outcome Study design (PICOS) eligibility criteria for full-text assessment
Category Inclusion criteria Exclusion criteria
Participants Individuals with severe mental illness (SMI) ≥ 18 years.
Severe mental illness—bipolar affective disorder, schizophrenia,
schizoaffective disorder, psychosis, any psychotic disorder.
Individuals with SMI under the age of
18 years.
Intervention Pharmacy staff carrying out any of the following activities to any
degree:
Screening/monitoring for cardiometabolic risk or metabolic syndrome,
syndrome
X or cardiometabolic disease or related diseases and any of the
associated risk factors including lifestyle advice, diet, smoking,
alcohol, exercise, cardiovascular disease, diabetes or prediabetes, HbA1c,
glucose,
weight, BMI, waist circumference, overweight, obesity, lipids, lipid
abnormalities, blood pressure and hypertension.
Health promotion or risk reduction intervention for cardiometabolic
risk or metabolic syndrome, syndrome X or cardiometabolic disease
or related diseases or any of the associated risk factors.
Medicines management activities relating to the above.
Any of these activities carried out wholly by
staff who are not pharmacy staff.
Activities that are carried out by pharmacy
staff who are not listed.
Comparators (NB it is not
compulsory to have a
comparator for the study
to be included)
Patients with SMI ≥ 18 years who did not receive any intervention.
Patients who do not have SMI who have any intervention.
Outcome Primary outcome:
Change in rate of screening of cardiometabolic risk or metabolic
syndrome, cardiometabolic diseases or syndrome X or any of the
associated risk factors.
Change in health or lifestyle behaviour (risk reduction or health promotion).
Diagnosis of metabolic syndrome or identification of individual at
high risk of metabolic syndrome.
Diagnosis of diseases related to cardiometabolic risk metabolic
syndrome including diabetes, cardiovascular disease, hypertension,
obesity, overweight, diabetes/high risk of diabetes/pre-diabetes.
Change in patient or physical health parameter e.g. BP outcome for
the above.
Views, perception, opinions, experiences of service users, carers or
any care professionals on the role of pharmacy to deliver ANY of
the interventions.
Studies that do not measure the primary
outcomes.
Study design Any study design.
Any country.
Papers written in English only.
No study design will be excluded.
Papers not written in the English language.
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interventions for CMR, MetS and related diseases (iii)
implementation of clinical interventions for CMR, MetS
and related diseases.
For this review to be meaningful in informing clinical
practice, we wanted to gain an understanding of how
study interventions were implemented. To understand
this ‘how’, we undertook a two-step, detailed analysis
and review of the implementation strategies and their ef-
fectiveness with regards pharmacy or pharmacy staff in
CMR, MetS and related diseases. First, the individual im-
plementation strategies for the study intervention were
classified into five categories: ‘Professional’ (e.g. distribu-
tion of educational materials, reminders), ‘Organisa-
tional’ (e.g. provider-oriented interventions, structural
interventions), ‘Financial’ (e.g. provider incentives), ‘Pa-
tient-centred’ (e.g. patient education) and ‘Regulatory’
(e.g. peer review). This was done using the Cochrane Ef-
fective Practice and Organisation of Care Group (EPOC)
taxonomy classification system checklist [69] (Additional
file 3) independently by all three authors (DS, EL, RM)
with discrepancies being resolved through discussion be-
tween three authors (DS, EL, RM).
Second, an analysis of implementation strategies identi-
fied was undertaken using the Cochrane EPOC tax-
onomy classification system checklist [69]; within each
category the individual implementation strategies were
identified. For example, within the category of ‘Profes-
sional’ the individual implementation strategies used to
implement the study intervention could be the distribu-
tion of educational material or reminders. This was only
carried out for those studies where impact of the study
intervention could be assessed from quantitative outcome
data provided (statistical tests of significance of data ob-
tained for outcome parameters reported by study authors)
(e.g. rate of screening for MetS before and after imple-
mentation of study intervention). Qualitative data was not
analysed for this part of the review. Outcomes were fur-
ther distinguished as being either a process outcome (e.g.
rate of identification of metabolic syndrome) or a clinical
outcome (e.g. smoking cessation or weight loss) [70].
Fig. 1 Preferred Reporting Items for Systematic for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of search results
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The results of statistical tests of significance of data
obtained for outcome parameters reported by study au-
thors were used to classify studies into three categories
as follows (see Table 7):
↑ or ↓ (bold) statistically significant change in all out-
come parameters
↑ or ↓ statistically significant increase in at least one
but not all outcome parameters
= no statistically significant change
Results
Study selection and study characteristics
Thirty-four studies were identified (Fig. 1) but the results
of two of these were combined [71, 72] and analysed as
one study as the findings were both realised from a sin-
gle research study. The 33 studies showed heterogeneity
for all characteristics and outcomes (Table 2). The ma-
jority of these (n = 25) were quantitative, 4 were qualita-
tive [73–76] and 4 of a mixed methods [77–80] study
design. Twenty of these studies included a study inter-
vention where quantitative outcome data allowed for im-
pact to be assessed—statistical tests of significance of
data obtained for outcome parameters reported by study
authors (a pre-post study design (n = 14)) or they com-
pared groups where study intervention was implemented
against group where the study intervention was not im-
plemented (a case-control study design (n = 5) [78, 79,
81–83] or randomised controlled study (n = 1) [84].
Table 3 shows that the most common setting for
study intervention was a community mental health/psy-
chiatric outpatient clinic (n = 15), followed by psychi-
atric inpatient wards (n = 12). Four studies were based
in primary care settings (community pharmacy (n = 1))
[80], one in a General Practitioner (GP) surgery [85] and
two in a primary care clinic [81, 82]. One study was
based in early intervention/psychosis services [86] and
one based in other (mix of urban, non-urban and metro-
politan centres) [71, 72]. Pharmacists were involved to
some extent in delivering the interventions across all
studies, and those involved were mostly commonly
specialist mental health/psychiatric pharmacists (n = 9)
[73, 79, 83, 85–90] or clinical pharmacists (n = 9) [76,
78, 81, 82, 91–95] (Table 4). Differences in terminology
across studies due to differences in country of origin did
not allow us to differentiate grades or qualification of
pharmacists. Pharmacy technicians were involved in one
study [85] and community pharmacists were involved in
one study [80]. Two studies made a broad reference to
pharmacy team involvement but did not specify particu-
lar pharmacy roles [75, 80]. There was a lack of diversity
in the country of origin of the studies: 53% (n = 18) were
conducted in the USA and 35% (n = 12) were conducted
within the UK (Table 1).
Summary of quality assessment
The overall quality of the reported studies, assessed
using the Mixed Methods Appraisal Tool (MMAT) [67,
96] was generally good, with twelve studies scoring ****
(100%), eight studies scoring *** (75%), and thirteen
studies scoring ** (50%) or less. (Additional file 2: 1.3
provides detailed information). Table 5 provides a
summary.
A limitation was identified amongst those studies
which utilised qualitative data—the authors of the stud-
ies were not clear about how collecting qualitative data
was relevant to answer the research question. Another
limitation included either not reporting (n = 4) [74, 76–
78] or providing a justification for, method of data ana-
lysis [79]. Lack of reporting of researcher reflexivity
within qualitative studies (n = 3) [74–76] and qualitative
aspects of mixed methods studies s (n=4) [77–80] were
also identified as limitations amongst all of these studies.
All four mixed methods studies [77–80] exhibited lim-
itations and scored poorly (50% or less) . These studies
were not described by their authors as being ‘mixed
methods’, but all included the collection and analysis of
both qualitative and quantitative data with the purpose
of meeting the overall research objective. Of these, one
[79] made reference to the use of mixed data being as
being relevant to the research questions. Not unsurpris-
ingly, therefore, all four mixed methods studies scored
zero for integration of both qualitative and quantitative
data, there was no evidence of findings from different
methods being integrated through the results, or any dis-
cussion of integration within the published papers.
The randomised controlled study [84] identified for
this review scored poorly (25%) due to lack of descrip-
tion of participant allocation, < 80% reporting of out-
come data and a high rate participant attrition (> 20%).
Quasi experimental approaches were utilised in thirteen
[86, 88, 92, 94, 95, 97–104] of the quantitative, outcome
studies, (n=12) [86, 88, 92, 94, 95, 97–101, 103, 104] of
these scored more than 50%. Seventy-one percent [71,
85, 87, 90, 91, 93] (n = 5) of the quantitative descriptive
studies scored 50% or more.
Collective appraisal of data: Mapping review (Fig. 2) and
detailed analysis and review of the implementation
strategies used in study interventions (Table 6 and Table 7)
Mapping review (Fig. 2)
Role of pharmacy in the healthcare pathway (Fig. 2)
The mapping review included all 33 studies (quantita-
tive, qualitative and mixed methods). Figure 2 shows the
key components of the healthcare pathway for CMR,
MetS and related diseases and the role of pharmacy at
each key component; fourteen studies [73, 79–81, 83, 84,
86, 87, 89–91, 93, 100, 102] included pharmacists in
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Method Study type Participant characteristics Results
MacHaffieb,
2002, UK [105]
Sources of health promotion















41 adult (age > 18 years)
patients with a 12 month
prevalence of serious and
persistent mental illness (12
with schizophrenia, 11
schizoaffective disorder, 9
bipolar I, 4 bipolar II, 1
psychotic disorder not
otherwise specified (NOS), 3
major depressive disorder, 1
panic disorder) or a lifetime
prevalence of these disorders
accompanied by evidence
that they would have been
symptomatic in the last 12




and pharmacists (in that
order) as providing the













and monitoring initiated by
prompt referral to suitable
specialist services or general
practitioners
Joint working agreement
with other teams including
pharmacy put in place prior
















Results from study relate to
the intervention of the nurse
advisor. Direct impact of




Impact of a protocol for
monitoring weight and





Quant Pre and post
measurements: quasi
Adults aged > 18 years .61









in recording of admission
weight or blood glucose was
observed.
Ongoing monitoring of
weight after admission was
significantly more common.
For only 29% of patients
studied in 2004 was there














Quant Audit pre and post
intervention: quasi





(ICD)-10 F20-29), 260 (13.2)
had bipolar disorder (ICD-10




bipolar disorder, 54 (3.7%)
other.
Measurement or test result
was recorded in the clinical
records in the previous year
(2005):
Baseline -BP in 26% of this
sample, for BMI (or other
obesity measure) in 17%, for
plasma glucose (or
glycosylated haemoglobin
(HbA1c)) in 28% and for
plasma lipids in 22%.
1 year after intervention—BP
in 43% of this sample, for
BMI (or other obesity
measure) in 34%, for plasma
glucose (or HbA1c) in 38%
and for plasma lipids in 35%
Predictors of what clinical
factors might be related to
full metabolic screening:
- At baseline, age and a
known diagnosis of
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Method Study type Participant characteristics Results
dyslipidaemia
- At 1 year re-audit: known
diagnosis of diabetes and
type of antipsychotic, relat-




Compare the efficacy of a
pharmacist led
cardiovascular risk reduction
clinic (CRRC) in the lowering
of cardiovascular risk







Adults aged > 18 years; total
of 297 of whom 176 had no
mental health condition
(MHC); 121 had a MHC of
which 92 (76.0%) had a non-
severe MHC diagnosis and
29 (24.0%) had a severe MHC
(schizophrenia, schizoaffec-
tive disorder, bipolar dis-
order, psychosis not
otherwise specified or post-
traumatic stress disorder with
psychosis).
The mean United Kingdom
Prospective Diabetes Study
cardiovascular risk score
change from baseline is
comparable for those
without a mental health
condition vs those with a
non-severe mental health





Usefulness of a metabolic
risk screening program,
including point-of-care glu-
cose testing, to quantify









Adults aged > 18 years. Total
participants (92) all of whom
were on an antipsychotic.
Diagnoses were recorded in
88, 53 (60%) schizophrenia or
schizoaffective disorder, 18
(20%) bipolar disorder and
17 (19%) major depressive
disorder.
63 (71%) met criteria for level
1 metabolic risk (abdominal
obesity); of these 63 patients,
38 (60%) met criteria for level
2 risk (abdominal obesity
plus hypertension).
Patients with a random
glucose level greater than
140mg/dl had a higher
likelihood for being at level 2
risk than level 1 risk
Women had a significantly





of level 1 risk and BMI
greater than 30 kg/m2
compared with Caucasians.
Patients with a BMI greater




Overall, 5 (5%) of the 92








pharmacist made over a 6







Quant Retrospective chart review. Total participants (34)—who




bipolar disorder, or major
depressive disorder.
Physical health assessments,
review of blood glucose
logs, BP undertaken when
appropriate (e.g. recent
development of diabetes or
hypertension). Labs
recommended by
pharmacist to monitor for
adverse effects and disease
states (15 times). Coordinate
care with other healthcare
providers, including those
not part of the mental health
care team - included
recommendations made to
primary healthcare providers
on non-psychiatric issues in-
cluding blood pressure,
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Method Study type Participant characteristics Results
diabetes control (12 times).
The interventions/recom-
mendations were part of a
study involving a compre-
hensive medicines manage-





psychiatric clinic to improve
adherence to medications





Quant Prospective single centre
pilot study: quasi
27 individuals > 18 years
with axis I diagnosis: 11
(41%) bipolar disorder 9
(33%) depression, 7 (26%)
other (not stated) receiving
at least one scheduled
medication for mental illness.
Quantitative
WHOQOL-BREF (abbreviated





changes in both the physical
capacity
Secondary Study Endpoints
Overall, there were no
significant changes in the
metabolic parameters
measured except for total





an increase in exercise,





of times) to: increase exercise
to promote weight loss and




(9). Patient self-reported ac-






Different models for the










Prospective. TRS (any age); 23 patient
participant questionnaire 10
patients’ clinic visit observed;
9 interviewed. 23 healthcare
professional survey,
Participants in the clinics
with a pharmacist reported
no difference in health,
wellbeing, self-efficacy and
ability to manage their own
health than clinics without
pharmacist input.
In terms of the most
favourable behaviours:
- Doctors scored favourably
in 12 of the 19 areas, with
nurses and pharmacists
equal in 4 of 19 and




8 of the 19 areas, with
nurses in 5 and doctors
and phlebotomists in 4 of
the 19. However when the
scores across all 19
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Method Study type Participant characteristics Results
domains were averaged
the findings demonstrated
with greater clarity the
participants’ perception of
the HCP communication




order entry (CPOE) pop-up
alert for laboratory metabolic
monitoring of patients







Before and after alert
(respectively):62 (36.3%) and
44 (28%) schizophrenia, 43
(25.1%)and 47
(29.9%)depressive disorders,
35 (20.5%) and 39 (24.8%)
bipolar disorder, 9 (5.3%) and
11 (7.0%) mood disorder
NOS, 6 (3.5%) and 4 (2.5%)
personality disorders, 2
(1.2%) and 2 (1.3%)
dementia, 2 (1.3%) and 6
(2.8%) anxiety disorders, 5
(2.9%) and 0 substance
related disorders, 4 (2.3%)
and 1 (0.6%) adjustment
disorder, 3 (1.8%) and 2
(1.3%) other. Age > 18 years.
Patients with glucose level
available pre-alert 158
(92.4%) and post alert 157
(100) p = 0.001. Blood glu-
cose level ordered at the
same time as the SGA or-
dered on the computer sys-
tem 9 (5.7%) and 31 (19.7%)
p < 0.0001. Patients with fast-
ing glucose level available
(overall) 80 (46.8%) and 110
(70.0%) p < 0.0001.
Patients with lipid panel
available 49 (28.7%) 117
(74.5%) p < 0.001. Patients
with both glucose level and
lipid panel available 47
(27.5%) 117 (74.5%) p <
0.0001. Patients with fasting
a lipid panel available
(overall) 32 (18.7%) 94
(59.9%) p < 0.0001
Blood glucose level ordered
at the same time as the SGA
ordered on the computer














Quant Retrospective chart review:
quasi
60 patients pre-intervention
and 60 patients post inter-
vention with a diagnosis of
schizophrenia (3.3% pre and
13.3% post), schizoaffective
disorder (33.3% pre and 30%
post), bipolar disorder (40%
pre and 23.3% post) and
major depressive disorder
(16.7% pre and 21.7% post)
The physician education
program was successful in
significantly increasing the
assessment of HbA1c values
and lipid profiles for patients















Quant Retrospective quasi Pre-intervention total of 33
patients of whom 7 (22%)
schizophrenia, 9 (27%)
bipolar, 13 (39%) psychoses.
Post-intervention total of 30
patients of whom had 6
(20%) schizophrenia, 10
(33%) bipolar, 5 (17%) psych-
oses. Aged 18-65 years on in-
patient ward ≥ 48 h.
In the pre-intervention
group. Patients with schizo-
phrenia were significantly
more likely to have baseline
lipid monitoring. In the post-
intervention group in com-
bined data, patients with a
diagnosis of diabetes were
more likely to have baseline
lipid and glucose/HbA1c.




Implementation of a high-




Quant Quasi Total of 36 patients in the
first audit cycle of whom 14
(38.9%) schizophrenia/
schizoaffective disorder, 5
(13.9%) bipolar disorder, 7
(19.4%) unipolar depression
and 7 (19.4%) dementias.
Second cycle (after the
intervention) total of 38 of
Glucose and cholesterol
levels were monitored at
baseline in only 44% and
16%, respectively, of patients
in the first audit, although
both of these showed
significant improvement by
the second audit.
The proportion of patients in
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Method Study type Participant characteristics Results
whom 12 (31.6%)
schizophrenia/schizoaffective






measured 3 monthly after
starting antipsychotic
medication increased from
41.7% and 25%, respectively,
in the first audit to 66.7% for




cardiovascular risk were not
significantly affected by the
risk profile of the
antipsychotic prescribed
either in 2008 or in 2010,
except for the annual
cholesterol monitoring rate,
which was paradoxically
lower for the high-risk anti-
psychotics than the all-













Analysis of information from
database for psychotropic
monitoring




to schizoaffective disorder or
bipolar disorder with
psychotic features.
Orders for fasting blood
glucose were discontinued
and changed to ‘attempt
fasting status’ and ‘obtain
HbA1c’ and scheduled for
every 6 months.
Annual lipid panels were




Outreach visit by clinical
pharmacists (providing




Quant Retrospective: quasi A total of 205 adult (≥ 18
years) patients were included
– 93 active implementation
and 112 passive
dissemination. Individuals
with SMI (ICD-10 criteria for
schizophrenia (F20.0—20.99)
or affective (bipolar) disorder
(F30.0—31.99).
A significant improvement of
the use of the screening









Follow up study of Taveira—
maintenance of glycaemic
control and blood pressure







Quant Retrospective Total of 231 adults, 108 of
whom had mental health
conditions—breakdown not
given for diagnoses
There was no significant
difference between diabetic
patients with and without
mental health conditions in
maintenance of HbA1c and
























Approximately 90% of the
patients with weight gain (n




intervention). If it exceeded
7% of the initial weight after
10 weeks, then switching to
another antipsychotic was
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tests to reduce of metabolic
syndrome risk parameters at










Total 120 patients (60
received pharmacist
intervention and 60 no
pharmacist intervention).
Anxiety disorders (76.7%, n =
89) (including posttraumatic
stress disorder [n = 12] and
obsessive-compulsive disor-
ders [n = 3]), depressive dis-
orders (65.8%, n = 79),
bipolar disorders (47.5%, n =
57), schizophrenia (30.8%, n
= 37), and schizoaffective
disorder (22.5%, n = 27).
No statistical differences in
metabolic syndrome based
on point-of-care tests were
observed between the 2
groups (PCS and NCS) at
baseline or at 12 months
Barnes, 2015,
UK [98]
Programme of screening for
















disorders, 6% disorders of
adult personality and




Over the 6 years of the
programme, there was a
statistically significant
increase in the proportion of
patients for whom measures
for all 4 aspects of the
metabolic syndrome had
been documented in the
clinical records in the
previous year, from just over
1 in 10 patients in 2006 to
just over 1 in 3 by 2012. The
proportion of patients with
no evidence of any
screening fell from almost ½











Quant Retrospective chart review:
quantitative non-
randomised with a control
group.
Schizophrenia 49% (n = 89)
and schizoaffective disorder
23% (n = 42).
Age > 18 years on an
antipsychotic.88% (n = 180)
from community support
services and 12% (n = 24)
from primary care clinics.
Monitoring of weight, blood
pressure, fasting blood
glucose and fasting lipid
panels was significantly
better at the two primary
care clinics than the
outpatient psychiatric clinic.
Family history monitoring
took place at 57% of primary
care clinic visits was not a
statistically significant
different.




weight and blood pressure.
Waist circumference was not










Quant Retrospective: quasi Adults with primary
diagnosis of schizophrenia or
schizoaffective disorder.
Number of patients not
stated
Adherence to guidance for
metabolic monitoring (March
2014, 76.7%; March 2015,
81.6%),
Cognitive behaviour therapy
for psychosis referral (March
2014, 6.5 %; March 2015, 11.
4 %) and vocational
rehabilitation referral (March
2014, 36.6 %; March 2015,
49.1 %) were increased after
clinical practice guideline
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Method Study type Participant characteristics Results
implementation.











order entry pop-up alert for
laboratory metabolic moni-
toring of patients treated
with second generation
antipsychotics.
Interventions carried out by











Retrospective chart review This is a follow on study
from DelMonte and reports a
third set of results. In this
group there were a total of
129 patients of whom 47
(36.4%) schizophrenia, 34
(26.4%) depressive disorders,
21 (16.3%) bipolar disorder,
10 (7.8%) mood disorder
NOS, 4 (3.1%) personality
disorders, 1 (0.8%)dementia,
6 (4.7%) anxiety disorders, 4
(3.1%) substance related
disorders, none with
adjustment disorder, 2 (1.6%)
other. Age > 18 years.
Quantitative
No significant decrease in
monitoring of glucose levels











The interventions made by




tests, but instead reviewed




Dietary teaching tools for a
select population diagnosed
with a severe mental illness
and limited financial ability.
A clinical pharmacist
(certified in diabetes


















Second patients who have a
primary diagnosis of
schizophrenia, schizoaffective
disorder, or bipolar disorder
(number of patients not
stated).
Phase one: Ten cards were
created and distributed to
the healthcare professionals
(HCPs). A focus group was
conducted. HCPs reported
the cards were useful in
opening dietary choices




Phase two: From focus
group feedback, specific







Case of an individual with
refractory schizophrenia who
developed rapid-onset insu-
lin dependence at the com-




Quant Case report One individual with TRS Case report of an individual
with refractory schizophrenia
who developed rapid-onset
insulin dependence at the
commencement of his cloza-
pine therapy and in whom





Pilot study of process and
impact of implementation of
the Lester tool
(cardiometabolic health








disorder or other psychotic
disorders. Focus group with
5 service users
Questionnaire based survey:
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Method Study type Participant characteristics Results
Assess the extent to which
the Lester tool may be








Focus group: 5 individuals
Implementation of electronic
tool developed by pharmacy
team: 52 patients baseline 29
at follow-up
(1) Which health care
professional(s) would you
speak to if you thought your
medication for your mental
health was having a bad
effect on your physical
health? Of 533 only 3 (0.6%)
stated pharmacist
(2) Where do you get
information about how to be
physically fit and healthy? Of
564 none stated a
pharmacist
One hospital NHS trust were






developed an electronic tool
for collection of
cardiometabolic health data.
Data entry was completed
by ward clerk Informants
attributed the shift in the
types of interventions
offered (e.g. reduction in
medication reviews, and
increase in offers of advice
regarding exercise and diet)
to improved confidence
amongst ward staff, meaning
that they were more likely to
offer to intervene
themselves, rather than to
refer service users to other
professionals (doctors or
pharmacists).
One trust had a Physical
Health Strategy Group is the
governance group for
physical health care
Focus group activity with 5
service users
(1) To what extent did you
feel you were given
information about potential
adverse physical effects of
medication and were
empowered to make a
decision weighing up the
risks and benefits? The
mental health trust has a
good pharmacy website—
but it is not clear how many




New model of care—
integrated care programme
approach review involving






Prospective Individuals on care program








Patient feedback about the
whole service was positive
(waiting time, involvement in
decision making,
management plan explained)
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clinic through a retrospective




Quant Retrospective: descriptive 163 in total - 90 subjects
schizophrenia (55.2%), 45
with psychosis not otherwise
specified (27.6%), 19 with
schizophreniform disorder,




reported tobacco use, and
47 subjects admitted to illicit
drug use (primarily
marijuana). Nearly one-fourth
of subjects also met diagnos-
tic criteria for dyslipidaemia
or obesity at some point in
the study, with lesser de-
grees of hypertension and
diabetes mellitus; no subjects
met criteria for a cardiometa-
bolic abnormality according
to baseline data.
As a result of the use of the
tool the following
interventions were made—
referral to dietician or health
program n = 29 (17.8%), start
diabetes medication n = 13
(8.0%), adjust diabetes
medication 2 (1.2%), start
dyslipidaemia 1 (0.6%).
Dyslipidaemia and obesity
were (later) found after use
of clinical decision support


















induced psychosis and any
other diagnosis.
Data for inpatient audits 252
patients per year for 3 years
2014-2017, early intervention
audit 150 patients per year
for 2 years 2016-2017, 900
community mental health
patient.
Improvement in rate of
screening and monitoring
Rate of screening alone in
2013 was 24% (average)
Rate of screening and
related interventions (total)
was 87% as measured 2015
inpatient only
In 2016 99% for inpatients
and 95% for early
intervention team
In 2017, 100% for inpatient,
97% for early intervention
and 87% for community






in a nursing home will
decrease overall rates
antipsychotic use. This study
also measured HbA1c done
in past year and lipid panel




Quant Prospective single centre:
quasi
81 patients in total who
were residents at the nursing
home, of these 14 had a
concomitant diagnosis of
dementia and at least one of
the following diagnoses:
schizophrenia, bipolar, or
depression; 31 had dementia




58% (33/57) to 83% (45/54)
(p = 0.003), however, not










Practices and attitudes of
Australian mental health
practitioners towards
assisting their clients to stop
smoking and their beliefs
about potential Tobacco
Harm Reduction strategies
for people with SMI.
Pharmacist (not further









and social workers) 66 (24.7),
community mental health






88.4% believed that tobacco
harm reduction strategies are
effective for reducing
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Method Study type Participant characteristics Results
specified)




others (not defined) 29 (3.4).
smoking related risks
77.9% believed abstinence
from all nicotine should not
be the only goal discussed
with smokers with SMI
56.9% were unsure about




more likely to help their




current smokers were less
likely to adhere to the 5As
(5As = ask, assess, advise,
assist, arrange) of smoking
cessation intervention.
The results of this study
emphasise the importance












Quant Pre and post study of
metabolic parameter
measurements: quasi
Survey of Mental health
professionals
Referral rate to pharmacist
clinic was 24 patients prior
to intervention, and 33
patients post intervention.
However, outcome data only
reported for 17 (51.5%) of
the 33 referred post
intervention. No breakdown
given as to how many have
SMI – but authors report that
at the facility 85.9% of
patients with a diagnosis of
schizophrenia had an active
prescription for an
antipsychotic.
9 mental health professionals
completed the survey.
There was a 37.5% increase
in overall referral rates to the
clinic after intervention, but
only 51.5% of patients
attended appointments as
scheduled.
Monitoring of vital signs
increased, but monitoring of
laboratory parameters
decreased.
60% (9 of 15) of providers
completed a survey, of
which one third indicated
they still forget to refer







secondary care for physical
health checks for those with
psychotic illness and provide




pharmacy but not clear if
members of staff other than
the community pharmacist



















180 patients with psychotic






psychiatric nurses not stated
70% attended the
community pharmacy. 71%
of those that attended had
all four screening parameters
measured (BP, BMI, glucose,
lipids) compared to 36%
before the intervention was
implemented.
100% of patients received
health coaching for smoking,
exercise and diet (22—stop
smoking; 56—exercise; 78—





score of 52.72; 2nd
appointment 41 patients
completed with an average
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Method Study type Participant characteristics Results
score 57.26 and at the 3rd
appointment 15 patients
completed with an average
score of 58.46.
100% of CPA coordinators—
data on satisfaction was
unclear; 100% of patients
agreed/strongly agreed with
the time taken to get an
appointment and support
received.
Qualitative data from 4
community pharmacists—












GP surgery in primary care
Quant Prospective Primary care (GP) severe
mental illness registers of 5
GP surgeries were reviewed
by pharmacy technicians
(total 472 patients). 316
(67%) of these patients were
prescribed mood stabiliser or
antipsychotics. Pharmacists
received referral for 197
patients and undertook
interventions for physical
health issue (blood tests
or electrocardiogram) in 22
of these.
Blood tests were overdue in
16 (73%) cases and out of
range in 6 (27%).
Out of range and overdue
bloods were followed up
with the appropriate team.
Reasons for overdue include:
failure to attend despite
requests, patient being out
of the country for a long
period of time or query
regarding whether tests
were to be done in
secondary or primary care.
Quant: Quantitative. Qual: Qualitative.
aTaylor [73], Quirk [75], Shanker [76] and Raynsford [85] included some work and results that were completely irrelevant objectives of this literature review: we will
only consider those aspects pertinent to our review question
bAsked the opinion/views of an individual with SMI
Please note that none of the studies included informal carers of those with SMI
The dataset was heterogeneous for many characteristics including participant characteristics such as definition of SMI and age, study setting, outcomes measured
and data collected and did not allow for quantitative data to be pooled or examined by meta-analysis. The authors (DS, EL, RM) used the following methods to
analyse the data: (i) a mapping review and (ii) implementation strategies used to implement the study intervention were classified using the
Cochrane EPOC taxonomy







Primary care (primary care clinic) 2









aTwo papers from the same study
Table 4 Summary of pharmacy staff type of included studies
Pharmacy staff type Number of
studiesa
Head of pharmacy/pharmacy manager 4





Clinical pharmacist with extra /additional qualifications 2
Specialist mental health psychiatric pharmacy technician 1
Community pharmacy 1
Community pharmacy team 1
Pharmacy team 1
1st year pharmacy resident (pharmacist) 1
Hospital pharmacist 1
aTotal not provided as some studies used more than one staff type in the
implementation of study intervention
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Taylor [73] ✓ ✓ ✓ ✓ ✓ ✓ ****
McMorris [74] ✓ ✓ ✓ X ✓ X ***
Quirk [75] ✓ ✓ ✓ ✓ ✓ X ***
Shanker [76] ✓ ✓ X X ✓ X *
Quantitative: randomised controlled trial
Clear
question
















Schneiderhan [84] ✓ ✓ ✓ X X X *
Quantitative: non-randomised (assessed using modified assessment criteria)
Clear
question

















Runcie [100] ✓ ✓ ✓ X ✓ ✓ ***
Barnes [101] ✓ ✓ ✓ ✓ ✓ ✓ ****
Schneiderhan [89] ✓ ✓ ✓ ✓ ✓ ✓ ****
Lizer [102] ✓ ✓ X ✓ X X *
DelMonte [88] ✓ ✓ ✓ X ✓ ✓ ***
McCleeary-
Monthei [103]
✓ ✓ ✓ ✓ X X **
Kjeldsen [92] ✓ ✓ ✓ ✓ ✓ ✓ ****
Ramanuj [104] ✓ ✓ ✓ ✓ ✓ ✓ ****
Sud [86] ✓ ✓ ✓ ✓ X ✓ ***
Koffarnus [97] ✓ ✓ ✓ ✓ ✓ ✓ ****
Barnes [98] ✓ ✓ ✓ ✓ ✓ ✓ ****
Fischler [99] ✓ ✓ ✓ ✓ ✓ ✓ ****
Sasson [94] ✓ ✓ ✓ ✓ ✓ ✓ ****






















Taveira [81] ✓ ✓ ✓ ✓ ✓ f✓ ****
Cohen [82] ✓ ✓ ✓ ✓ ✓ ✓ ****


















MacHaffie [105] ✓ ✓ X X ✓ X *
Gable [90] ✓ ✓ ✓ X ✓ X **
Lucca [91] ✓ ✓ ✓ ✓ X ✓ ***
Porras-Segovia [93] ✓ ✓ ✓ ✓ ✓ ✓ ****
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more than one key component. Twenty-seven [75, 79–
81, 83, 84, 86, 87, 89–91, 93–95, 97–102, 104] of the 33
studies included direct (e.g. pharmacist undertaking
screening such as weight measurements or blood tests)
and indirect (e.g. pharmacist writing protocols for other
healthcare professionals to use) roles in screening. Ten
studies included identification of high risk, abnormal re-
sult or diagnosis of disorder, e.g. MetS [73, 79–81, 83,
84, 86, 87, 89, 100]. Ten studies [73, 79–81, 86, 87, 90,
91, 93, 102] included a clinical intervention for health
promotion or risk reduction delivered directly by
pharmacist to the patient. Five [79, 81, 86, 90, 91] also
included pharmacists referring to external care profes-
sional/service as a result of identification of risk, abnor-
mal result or diagnosis of disorder.
Role of pharmacy in other activities The mapping re-
view also shows pharmacists roles in other activities.
This includes a pharmacist as part of a physical health
strategy group [75] and clinical pharmacists creating
Table 5 Quality assessment (using modified Mixed Methods Appraisal Tool (MMAT)) [67, 96] (Continued)
Bozymski [87] ✓ ✓ X X X X ***
Sharma [71, 72] ✓ ✓ X ✓ ✓ ✓ ***


















MacHaffie [105] ✓ ✓ X X ✓ X *
Gable [90] ✓ ✓ ✓ X ✓ X **
Lucca [91] ✓ ✓ ✓ ✓ X ✓ ***
Porras-Segovia [93] ✓ ✓ ✓ ✓ ✓ ✓ ****
Bozymski [87] ✓ ✓ X X X X ***
Sharma [71, 72] ✓ ✓ X ✓ ✓ ✓ ***































✓ ✓ X X X * *** Qualitative *
Watkins
[78]
✓ ✓ X X X * **** Qualitative *



































✓ ✓ X X X * *** Qualitative *
Watkins
[78]
✓ ✓ X X X * **** Qualitative *




✓ ✓ ✓ X X ** ** N/A both equal **
✓Yes or methodologically sound; X, no or not methodologically sound
?Cannot tell whether methodologically sound or not
Quality Appraisal of Included Studies Score: *(25%) **(50%) *** (75%) **** (100%)
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visual aids/dietary choices tools for use by care profes-
sionals who look after patients with SMI [74].
Gaps in the evidence base As well as identifying the
key components of the healthcare pathway where phar-
macy have been involved, the mapping review also
highlighted important gaps in the published evidence
base where little or no literature was found: screening of
waist circumference and weight/weight change, cardio-
vascular and diabetes risk assessment using formal risk
assessment tools/calculators, role/involvement of com-
munity pharmacy or pharmacy staff (e.g. pharmacy tech-
nicians) within primary care, follow-up of individuals
after implementation of a study intervention, utilisation
of behaviour change techniques or community or family
support, and finally the views/perceptions/experiences of
patients, (their) informal carer or caregiving dyads and
care professionals where qualitative data synthesis had
been undertaken. Finally there was no specfic mention
of high dose or simultaneous use of two or more (also
known as polypharmacy which often results in high
doses of antipsychotics) or switching antipsychotics
based on risk of CMR, MetS and related diseases.
Assessment of weight gain Weight gain was part of the
screening undertaken by a pharmacist in two studies
[73, 91]; in one study around 75.7% of patients who
attended pharmacist-led clozapine clinic [73] gained
weight since starting clozapine. In the other study [91],
weight gain (n = 30) was the most commonly observed
adverse drug reaction observed by the pharmacist. The
latter study [91] also included ≥ 7% weight gain as a trig-
ger for referral to dietary support and antipsychotic
switch as recommended in current guidance [36].
Application of risk assessment tools/calculators
Three studies [81, 82, 86] included CVD risk assessment
and none included diabetes risk assessment using formal
tools/calculators. Fifteen percent of the studies [78, 87,
92, 99] included waist circumference as an outcome
measure—this may reflect a lack of understanding of its
importance as a predictor of CVD or lack of inclusion in
guidelines on which study protocols were based. Taveira
[81] concluded that patients with diabetes and with
mental health conditions (MHCs) achieve the same
CVD risk reduction (using a formal CVD risk assess-
ment calculator as an outcome measure) as those with-
out MHCs. The duration of enrolment with risk
Fig. 2 Mapping review
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reduction clinic required to achieve this was around 25%
longer than those without MHCs.
Follow up of patients after completion of the study
intervention We identified one study [82] that reported
findings of follow up of patients after study intervention
had been completed [81]; these patients received usual
care between the study intervention and the point of col-
lection of outcome data for follow up. This study con-
cluded that there was no significant difference in the
duration of maintenance of blood pressure and HbA1c
up to 3 years after people with diabetes with MHCs were
discharged from a pharmacist-led cardiovascular risk re-
duction clinic [82]. The authors point out that their
model of care was effective for treating particular spe-
cific aspects of CMR or MetS or related diseases in pa-
tients with and without MHCs but that more work is
needed for specific mental health conditions and
whether further benefits could be gained by treating
both MHCs and physical health conditions concurrently.
This study did not provide detailed breakdown of out-
comes for those with SMI (instead of reporting results
for those with SMI under the general heading of MHCs
which included a mix of diagnoses: schizophrenic dis-
order, episodic mood disorders including depression, bi-
polar disorder, depressive disorder and anxiety).
Detailed analysis and review of implementation strategies
of study intervention using the EPOC taxonomy (Tables 6
and 7)
Studies that included quantitative data that allowed for
assessment of impact of study intervention (study authors
had undertaken statistical tests of significance of data
obtained for outcome parameters)
Table 6 shows a summary of the implementation strat-
egies used in the study intervention using the EPOC tax-
onomy as well as which of these allowed for assessment
of the study intervention to be assessed. Detailed ana-
lysis of the 20 studies that included quantitative outcome
data (classified as being process or clinical) that allowed
for assessment of the impact of the study intervention is
shown in Table 7 (authors reported quantitative data for
groups being compared, e.g. study intervention vs no
study intervention and statistical tests of significance of
data obtained for outcome parameters reported by study
authors). These studies were published between 2007
and 2018. The most frequently used implementation
strategies identified using the EPOC taxonomy [69] were
those orientated towards healthcare professionals and
patients. Of the healthcare professional-oriented imple-
mentation strategies, distribution of educational mate-
rials (published or printed recommendations for clinical
care, including clinical practice guidelines for CMR or
MetS or related diseases) was the most commonly used
(45%) (n = 9) [80, 86, 92, 95, 97, 98, 100, 101, 104]. Re-
minders (e.g. computer pop-up alert) was the next most
commonly used strategy being applied in 30% (n = 6)
[78, 79, 86, 88, 95, 103]. With regards patient-orientated
interventions, the use of face-to-face education, educa-
tional materials, reminder cards and questionnaires was
applied in 25% (n = 5) [78, 80, 81, 84, 102], 20% (n = 4)
[95, 98, 101, 102], 10% (n = 2) [98, 101] and 10% (n = 2)
[98, 101] of studies respectively. Two finance-orientated
interventions (provider incentive [86] (UK) and patient
incentive [95] (USA)) were used in any of the studies.
The total number of implementation strategies used
varied from 0 to 10 per study. The overall median num-
ber of implementation strategies used per study was
three. Sixteen studies reported process outcomes only,
three [81, 82, 102] clinical outcomes only, and one [80]
both process and clinical outcomes. The relationship be-
tween the total number of implementation strategies
used and the impact on the outcomes measured is un-
clear. The quality assessment data for these studies is re-
ported below.
Process outcomes Process outcomes included screening
for CMR or MetS or related diseases and rate of identifi-
cation of MetS. In those studies in which there was a
statistically significant improvement in process outcomes
(n = 7), 50% used 7 or more implementation strategies
[86, 98, 101], 60% used educational materials [86, 92, 98,
101], 50% used educational meetings [86, 98, 101], and
50% used audit and feedback [86, 98, 101], all targeted at
healthcare professionals. Studies using a smaller number
of implementation strategies (3 or less) [88, 92, 94] also
reported achieving significant improvement in process
outcomes; all of these had one thing in common—some
form of face-to-face contact between healthcare profes-
sionals (pharmacist-led multidisciplinary team) [94],
educational outreach [92] and local opinion leaders [88].
Including pharmacists alone as part of the clinical MDT
team as the sole implementation strategy resulted in sig-
nificant improvement in process outcomes in two stud-
ies [83, 94].
Reminders (e.g. pop up alerts on computer systems)
were a frequently used implementation strategy within
the studies. Despite this, their use alone does not appear
to be associated with significant improvement in process
outcomes. In one study, a pharmacist produced a tem-
plate reminding clinicians to undertake screening and
attached this to the medication charts of patients with
SMI who needed screening [103]; this had no impact on
the rate of screening. In a study by DelMonte et al. [88];
a pharmacist-designed computer pop-up alert and
‘champion psychiatrist’ formed part of an intervention to
improve the uptake of blood tests for CMR or MetS or
related diseases: they found that the majority of blood
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tests were ordered at the same time as the pop-up alert.
However, a follow-up study conducted a few years later
using the pop-up alert alone [79] revealed a statistically
significant decline in the number of blood tests ordered
within 24 h of the reminder; suggesting that the cham-
pion psychiatrist was the more effective aspect.
All of the studies in which there was a statistically sig-
nificant improvement in all process outcomes scored
***(75%) or more in the quality assessment except one
[83] which scored **(50%). Where studies were mixed
methods that studies the quality assessment score for
the quantitative aspect of the study has been quoted
here as this part of the review was specifically concerned
with quantitative data.
Clinical outcomes Three studies investigated the im-
pact of study interventions on clinical outcomes only
[81, 82, 102] two of which [81, 82] scored **** (100%)
and the other [102] * (25%) in the quality assessment.
Two of these three studies were linked to each other in
that one [82] was a follow-up study of the other [81].
We included the follow-up study [82] in our review des-
pite the fact that it did not directly include the imple-
mentation of a study intervention; this 3-year
observational study provided some valuable data and
insight on follow up and long term impact of the
pharmacist intervention (cardiovascular risk reduction
clinic) included in the first study [81]. The follow-up
study [82] found that there was no significant difference
between diabetic patients with and without mental
health conditions (including those with SMI) in main-
tenance of diabetic control (as measured by HbA1c) and
systolic blood pressure in the 3 years after discharge
from the cardiovascular risk reduction clinic.
In the other two studies [81, 102], patient-mediated
strategies and face-to-face patient education were imple-
mentation strategies that where both utilised. One of
these studies reported a significant improvement in a
measure of physical well-being (WHOQOL-BREF) [102]
and the other reported that a 25% longer (statistically
significant) enrolment time in the research study was
needed to achieve the same outcome in CVD risk reduc-
tion in diabetic individuals with mental health condi-
tions compared with those without [81].
Study intervention with a reduction in process
outcome One study reported a reduction in the rate of
screening for CMR or MetS or related diseases [95] was
conducted over a 4-month period. This study scored **
(50%) as part of the quality assessment.
Process and clinical outcomes We identified one study
[80] which looked at both process and subsequent clin-
ical outcomes. This study did not include any statistical
analyses or statistical tests of significance of outcome
data collected and scored ** (50%) as part of the quality
assessment.
Discussion
The primary aim of this systematic literature review was
to undertake a detailed analysis and review of the pub-
lished studies that exist exploring the role of pharmacy,
or pharmacy staff in CMR or MetS or related diseases in
individuals with SMI.
The majority (81% (n=27) of studies) of published evi-
dence exists, for specialist mental health or clinical phar-
macists involvement in screening either directly (e.g.
undertaking blood pressure, blood cholesterol measure-
ments) and indirectly (e.g. writing protocols for other
healthcare professionals to use) based in community
mental health/psychiatric outpatient clinics (45% of
studies (n = 15)) as well as inpatient settings (36% (n =
12)). Some evidence exists, 30% (n = 10), for pharma-
cist’s involvement in identification of individuals at high
risk for diagnosis of CMR, MetS or related disease and
in the provision of a clinical intervention for health pro-
motion or risk reduction, 30% (n = 10), (e.g. pharmaco-
logical interventions for management of hypertension,
type 2 diabetes, hyperlipidaemia). Almost 42% of studies
included a pharmacist in the study intervention at all
key components of this healthcare pathway from screen-
ing, through to identification of high risk, abnormal par-
ameter or diagnosis of disorder, e.g. metabolic syndrome
and then implementation of clinical intervention.
Sixty percent (n = 20) of studies included quantitative
outcome data (process or clinical) that allowed for as-
sessment of the impact of the study intervention. Of
these, 55% (n = 11) included a pharmacist undertaking
screening and 40% (n = 8) [79–81, 84, 86, 87, 100, 102]
included a pharmacist at all key components of the
healthcare pathway. Of those 20 studies 35% (n = 7)
[86–88, 92, 94, 98, 101] reported statistically significant
improvement in all process outcomes (e.g. rate of diag-
nosis of MetS) and 10% (n = 2) [81, 102] in all clinical
outcomes measured (e.g. physical health domain of
WHOQOL-BREF).
Factors that facilitate specialist mental health or clin-
ical pharmacist involvement in screening of CMR, MetS
and related diseases in those with SMI may include be-
ing part of and having a clearly defined role within a
multidisciplinary team; access to appropriate resources;
effective engagement with those with SMI; effective col-
laboration with multi-disciplinary team/management
within healthcare settings to facilitate set up and roll out
of services; clinical knowledge, skills and training (e.g.
taking bloods and ordering lab measurements); system-
atic approach (e.g. application of standardised care) and
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trusted member of healthcare team and enhanced roles
that include prescribing.
Very little evidence currently exists for the role of
community pharmacists or other pharmacy staff (e.g.
pharmacy technicians) within primary care settings.
This data primarily comes from the USA and the UK.
This finding has particular relevance within the UK,
where up to a third of people with SMI are treated
solely in primary care [106]. Even in countries with
very well developed secondary psychiatric care sys-
tems (including the UK) the role of primary care is
key [107]. Accessibility is a known social determinant
of health [108]. Recent work has shown that 90% of
the population can access a community pharmacy
within a 20 min walk from where they live [109]. In-
dividuals who experience the highest rates of
deprivation, which includes those with SMI, could
benefit the greatest from this level of access [108].
The use of high dose or polypharmacy are associated
with higher risk of CMR, MetS and related diseases
[1, 40] - no specific mention was made of these in
any of the studies. Switching to antipsychotics with a
lower risk of CMR, MetS and related diseases repre-
sents a potentially useful approach [36, 37], again
nothing specific was found in any of the studies.
These represent gaps in the evidence base.
Clinical outcomes were reported for two studies where
pharmacists were involved in activities other than
screening. So, pharmacy could have a role to play be-
yond screening and towards identification of risk, abnor-
mal result, diagnosis and implementation of clinical
interventions for CMR, MetS and related diseases. There
is a lack of data and studies on clinical outcomes and
studies that examine the link between specific process
outcomes (e.g. screening for diabetes using glycosylated
haemoglobin/HbA1c) and subsequent improvements in
clinical outcomes (e.g. improved diabetes risk or control,
diabetes risk calculators, cardiovascular risk calculators)
in those with SMI.
Very little evidence, however, was found for their in-
volvement in screening for weight, weight gain or
change or waist circumference. Surprising in light of the
fact that systematic reviews show that the prevalence of
overweight and obesity is two- to threefold higher in
those with SMI than that in the general population [28].
A recent study conducted in North America found
nearly 80% of a sample of over 10,000 people with diag-
noses of SMI to be overweight or obese [110]. Another
systematic review found that waist circumference en-
ables prediction of MetS with a sensitivity of 79.4% and
a specificity of 78.8% [111]. The IDF emphasises the im-
portance of waist circumference as a mandatory feature
of MetS [32]. Weight, weight gain and waist circumfer-
ence should be included in any screening intervention
involving pharmacists given the increased prevalence
and usefulness in predicting MetS.
Improving the physical healthcare for those with SMI
is a key component of current mental health guidelines,
policies and commission documents across the world
[112–116]. A recent cross-sectional study of 5091 pa-
tients with schizophrenia in secondary care psychiatric
services [117] found low rates of clinical interventions
for blood pressure (25.2%), cholesterol levels (19.9%) and
glucose levels (53.5%) and smoking (57.2%) where
screening indicated a need. They are also less likely to
receive treatment for cardiovascular conditions [118] or
diabetes [119]. This represents a potential opportunity
for pharmacy to become involved particularly as this re-
view has shown the significant and positive impact of
specialist mental health pharmacist/clinical pharmacists
on process outcomes (i.e. screening).
Where qualitative data was collected, this was not syn-
thesised by the study authors using any qualitative syn-
thesis methods and where it was the method of
synthesis was not justified. In addition, researcher reflex-
ivity was not reported; there was no examination or cri-
tique of how the researcher impacted on the study or
the participants for this data. As a result of this and the
heterogeneity that existed within the studies that col-
lected qualitative data utilisation of qualitative data in
our systematic review was limited (e.g. could not be inte-
grated with quantitative data).
We were able to use this qualitative data as part of our
mapping review. Qualitative research has the potential
to make significant contributions to health services and
policy research. It provides valuable insights into the
ways that health is conceptualised, experiences of health
and illness, dynamics of multi-disciplinary teams and nu-
merous aspects of care delivery [120]. In addition, the
potential value that the mixed methods approach of this
review has not been able to be fully realised.
Three quarters of the studies that utilised a mixed-
methods approach did not explain how this approach was
relevant to the answering research question and all mixed
methods studies failed to integrate the quantitative and
qualitative data collected. In the absence of integration,
the knowledge harvested is only equivalent to the sum of
that derived from a qualitative study and a quantitative
study undertaken separately, rather than achieving a
“whole greater than the sum of the parts” [121]. A lack of
robust mixed methods studies exist on this topic.
High-quality RCT data is lacking. Numerous good
quality studies quantitative studies exist which utilise
non-randomised (mainly quasi) and descriptive ap-
proaches. These quasi studies were performed at popula-
tion level and may therefore have included individuals
who may otherwise have been excluded from RCTs, e.g.
severely unwell. Quasi studies are also viewed as being
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more pragmatic evaluating the real-world effectiveness
of a study intervention implemented by clinical staff, ra-
ther than by research staff under research conditions
[122]. Therefore, quasi-experimental studies may also be
more generalisable and have better external validity than
RCTs [122]. However, bias can occur in these types of
study leading to a threat to internal validity (e.g. differ-
ences between active and control groups are not
accounted for) [122].
Secondary aims were to undertake a detailed analysis
and review of implementation strategies used in study
interventions and their effectiveness to inform practice
and to identify evidence gaps to provide a focus for fu-
ture research studies. Where impact of the study inter-
vention could be assessed from quantitative outcome
data, it was not clear from significant proportion of
those studies how the total number or type of imple-
mentation strategies were selected or decided upon to
facilitate the implementation of the study intervention.
None of the studies had any fidelity measures [123] nor
was it clear to what extent the strategy was implemented
in practice. Three studies discussed the process of iden-
tifying barriers in clinical practice [95, 98, 101] with sub-
sequent implementation strategies being developed/
chosen to target these barriers in one study [95]. In one
study, the authors acknowledge that information on the
actual implementation of the change intervention was
not collected from the health services that participated
[98].
The duration of time over which the study was con-
ducted is also important. The study that showed a re-
duction in the rate of screening for CMR or MetS or
related diseases [95] was conducted over a 4-month
period. The most likely explanation for this reduction in
the rate of screening is that current guidelines recom-
mend annual screening. This represents a fault in study
design for that study rather than a positive or negative
outcome of the study; it was not conducted over a clinic-
ally appropriate duration of time.
The relationship between the total number of imple-
mentation strategies chosen and the subsequent impact
on outcomes measured is unclear for either process out-
comes such as blood tests or clinical outcomes such as im-
provement in lipid results. What may be more important
is the specific type of implementation strategies chosen (in
other words the specificity of implementation strategy
chosen is important). With regards process outcomes, the
following strategies appear to be particularly effective:
educational materials, educational meetings, clinical audit
and feedback and any strategy that uses face-to-face inter-
action between healthcare professionals. The use of mul-
tiple strategies (> 1 strategy) carries with it an inherent
problem in determination of causality and then the effect-
iveness of individual implementation strategies when
more than one is used. Any overlap, repetition, synergy or
hindrance that may occur as a result is also difficult to de-
termine. Similar to other reviews, we were unable to find
any study where head-to-head comparison of different im-
plementation strategies was undertaken [70, 124]. We
have shown here that the role of face-to-face interaction,
such as a pharmacist-led multidisciplinary ward round or
pharmacist outreach visits is a specific aspect that is im-
portant in achieving a statistically significant impact on
both process and clinical outcomes.
Strengths
This systematic literature review used a robust system-
atic search strategy and data was appraised using vali-
dated tools and methodology. In addition, assessment of
methodological quality, mapping review and assessment
of the implementation strategies was carried out and
checked independently by three authors using an inter-
nationally recognised taxonomy [69]. The inclusion of
all types of study (qualitative, quantitative and mixed
methods) is also a major strength and reflects that stud-
ies and data/outcomes of all types contribute to our un-
derstanding of this area of clinical practice.
The authors of this review have important experience
which is directly relevant to the area of research of this
review. DS, EL, RM and IM have extensive experience
working as practising clinical pharmacists within multi-
disciplinary teams. DS, RM and IM also have extensive
experience of working within mental health settings and
both IM and EB have extensive experience of conducting
applied research within mental health settings.
The mapping review was conducted as a mixed-
methods review; this facilitated the identification of
trends or themes as well as identification of specific gaps
which would otherwise not have been possible if we had
only used either qualitative or quantitative studies.
Limitations
There are limitations at two levels within this review;
limitations at individual study level included in the in re-
sults and discussion and more general limitations with
this approach. Outcomes reported by studies may have
been impacted up on by factors external to the study
protocol such as concurrent healthcare or quality im-
provement programmes, initiatives or healthcare staff
that distracted or raised awareness of the study interven-
tion. This was acknowledged in some of the studies [79,
88, 98]. Improvements in outcomes reported may have
been an artefact arising from improved documentation
or systems rather than the intervention itself. Con-
versely, where less effective outcomes were found, this
may be due to data collection issues such as inability to
access records outside the study setting.
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Interpretation of the association between the imple-
mentation strategy, improved process and/or clinical
outcome is not possible without being able to assess the
effort that was put in to putting these into practice as it
was not reported—authors of the studies did not provide
detailed description of how the strategies were imple-
mented or to what extent.
A limitation of the use of any taxonomy is that the re-
sults presented show our interpretation of the main
method of delivery as described by the authors of the
study under review; some interventions cannot be deliv-
ered in a mutually exclusive fashion. For example, classi-
fication of a study as patient-orientated intervention
using “educational materials” could not have been com-
pletely free from “face to face education” by the health-
care professional who gave these materials to the
patient.
Other limitations of note include the following:
(1) Heterogeneity in healthcare setting, outcome
measures chosen and timing of intervention—this
makes it difficult to interpret what works for whom
in what circumstances
(2) Detailed exploration of and consideration was
given to possible ways in which the studies could
be compared; however, heterogeneity of aims,
study design/models delivered, population
demographics, data collected and outcomes
measured prevented integrated quantitative
synthesis/data pooling (e.g. meta-analysis).
Our review relied wholly on statistical analyses
carried out by study authors
(3) Studies where outcomes were recorded under
group headings rather than specific groups, for
example, pharmacy staff within healthcare
professionals group [71, 72], and those with SMI
within all individuals with mental health
conditions [81, 82]
(4) Lack of reporting of patient diagnosis; 19 studies
were excluded purely on the basis that diagnoses
were not stated—potentially important data or
information about the role of pharmacy may have
been lost, e.g. pharmacists role in medicines
optimisation of antipsychotics
(5) The search was restricted to articles published in
English, it is therefore possible that we failed to
retrieve all studies that may have been eligible for
addressing our research question
(6) Some of the studies identified for this review
reported the results of audits conducted
within healthcare settings. Within some of these
audits, the audit criteria allow for refusal or
decline by the patient (e.g. refusal to have a
blood test) to be recorded in outcome data
as being compliant (i.e. the same as someone
having a blood test). However, where research
studies are conducted, a refusal would be
regarded as attrition. As such this may have
resulted in an overestimation of the effect of
the study intervention for those where audit
data was being reported
Conclusions
The most important finding of this systematic literature
review is as follows: the sole use of face-to-face inter-
action (as an implementation strategy) between pharma-
cists and other healthcare professionals (e.g. as part of a
multi-disciplinary team on a ward) has been shown to
consistently and significantly improve the process out-
comes (e.g. rate of screening for a comprehensive set of
cardiometabolic risk factors or metabolic syndrome) for
those with severe mental illness. Implementation strat-
egies which did not include any form of face-to-face
contact appear to be less effective for process outcomes.
Despite being frequently employed within studies, the
sole use of reminders (e.g. pop-up alerts on computer
systems) appears to have no statistically significant im-
pact on process outcomes. We would recommend the
incorporation of face-to-face interaction as part of any
implementation strategy chosen and discourage the sole
dependence on pop-up alerts.
There is paucity of good quality qualitative and mixed
methods design studies which include clinical outcomes
and the association between specific process outcomes
and improvements in clinical outcomes and also studies
conducted in primary care with community pharmacy
teams. Qualitative data will provide important informa-
tion about the views, experiences and perceptions of key
stakeholders (e.g. patients, informal carers and care pro-
fessionals) about pharmacy. This type of data will inform
current and future practice as well as other qualitative
and quantitative research studies.
Mixed method studies would be instrumental in the
development and testing of interventions delivered by
pharmacy—in the development of the intervention,
during the evaluation of the intervention, and after
the follow-up and assessment of outcomes is com-
pleted. Mixed methods study designs also mitigate
some of the intrinsic weakness or intrinsic biases and
the problems that come from single method studies.
Studies conducted in primary care and community
are vital as there is great potential for impact; a sig-
nificant proportion of people with mental health
problems are cared for entirely within primary care
and a significant proportion of the population can ac-
cess a community pharmacy a short walk from where
they live.
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